.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Teva
Julphar
Johnson and Johnson
AstraZeneca
US Army
Merck
UBS
Queensland Health
Daiichi Sankyo
US Department of Justice

Generated: September 22, 2017

DrugPatentWatch Database Preview

Claims for Patent: ► Subscribe

« Back to Dashboard

Summary for Patent: ► Subscribe

Title:Fusion proteins of collagen-binding domain and parathyroid hormone
Abstract: Fusion proteins containing active agonist or antagonist fragments of parathyroid hormone (PTH) and parathyroid hormone related peptide (PTHrP) coupled to a collagen-binding domain are presented. The fusion proteins can be used to promote bone growth, to promote hair growth, to prevent cancer metastasis to bone, to promote immune reconstitution with a bone marrow stem cell transplant, to promote mobilization of bone marrow stem cells for collection for autologous stem cell transplant, and to treat renal osteodystrophy. Pharmaceutical agents comprising a collagen-binding polypeptide segment linked to a non-peptidyl PTH/PTHrP receptor agonist or antagonist are also presented.
Inventor(s): Gensure; Robert C. (New York, NY), Sakon; Joshua (Fayetteville, AR), Matsushita; Osamu (Okayama, JP), Ponnapakkam; Tulasi (New York, NY)
Assignee: Ochsner Clinic Foundation (N/A) National University Corporation Kagawa University (JP) The Board of Trustees of the University of Arkansas (N/A)
Application Number:14/743,629
Patent Claims:1. A composition comprising: a collagen-binding polypeptide segment covalently linked to a PTH/PTHrP receptor antagonist; wherein the collagen-binding polypeptide segment is a ColH or ColG bacterial collagen binding polypeptide segment or a segment of a collagenase, wherein the PTH/PTHrP receptor antagonist comprises a peptide selected from the group consisting of residues 7-14 of SFQ ID NO: 7, residues 7-33 of SEQ ID NO: 7, residues 7-34 of SEQ ID NO: 7, residues 7-34 of SEQ ID NO: 8, and SEQ ID NO: 11, wherein the collagen-binding polypeptide segment comprises residues 38-158 of SEQ ID NO: 1, a fragment of at least 8 consecutive amino acids from residues 38-158 of SEQ ID NO: 1 or is at least 90% identical to residues 38-158 of SEQ ID NO: 1.

2. The composition of claim 1, wherein the collagen-binding polypeptide segment and the PTH/PTHrP receptor antagonist are chemically crosslinked to each other or are polypeptide portions of a fusion protein.

3. The composition of claim 1, wherein the PTH/PTHrP receptor antagonist is a polypeptide and the N-terminus of the collagen-binding polypeptide segment is linked directly or through a linker polypeptide segment to the C-terminus of the PTH/PTHrP receptor antagonist polypeptide.

4. The composition of claim 1, wherein the composition further comprises residues 37-130 of SEQ NO: 2 covalently linked to the collagen binding polypeptide segment.

5. The composition of claim 1, wherein the collagen binding polypeptide segment comprises residues 38-158 of SEQ ID NO 1.

6. The composition of claim 1, wherein the composition comprises SEQ NO: 10.

7. The composition of claim 1, wherein the PTH/PTHrP receptor antagonist consists of a polypeptide selected from the group consisting of residues 7-14 of SEQ ID NO 7, residues 7-33 of SEQ ID NO: 7, residues 7-34 of SEQ ID NO: 7 and residues 7-34 of SEQ ID NO: 8.

8. A method of promoting hair growth in a mammal comprising: administering the composition of claim 1 to the mammal in an amount effective to promote hair growth.

9. The method of claim 7, wherein the composition is administered locally at the site of desired hair growth.

10. The method of claim 7, wherein the administration is by subcutaneous or intradermal injection.

11. The method of claim 7, wherein the mammal is afflicted with chemotherapy-induced alopecia.

12. A method of treating or reducing renal osteodystrophy in a mammal comprising administering the composition of claim 1 to the mammal in an amount effective to reduce renal osteodystrophy or renal disease in the mammal.

13. The method of claim 12, wherein the composition is administered by injection.

14. A method of treating bone metastasis of cancer in a mammal comprising administering the composition of claim 1 to the mammal in an effective to reduce the incidence of bone metastasis of cancer or slow the growth of metastatic cancer in the bone in the mammal.

15. The method of claim 14, wherein the composition is administered by injection.

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Inventors Patent Expiration Status Orphan Source
Advance Biofactures
SANTYL
collagenase
VIAL1019950011965-06-04► Subscribe Ochsner Clinic Foundation (N/A) National University Corporation Kagawa University (JP) The Board of Trustees of the University of Arkansas (N/A) Gensure; Robert C. (New York, NY), Sakon; Joshua (Fayetteville, AR), Matsushita; Osamu (Okayama, JP), Ponnapakkam; Tulasi (New York, NY) ► SubscribeRXsearch
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: ► Subscribe

Country Document Number Publication Date
Canada2683862Aug 02, 2016
Canada2683862Oct 16, 2008
Canada2930681Oct 16, 2008
Denmark2155874Aug 01, 2016
European Patent Office2155874Feb 24, 2010
European Patent Office2155874May 11, 2016
European Patent Office2155874Sep 01, 2010
European Patent Office3091075Nov 09, 2016
Spain2583002Sep 16, 2016
Japan2010523671Jul 15, 2010
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.


« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Farmers Insurance
Baxter
AstraZeneca
Healthtrust
Chubb
Deloitte
Harvard Business School
US Army
UBS
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot